In a notable medical development, Russia’s Gamaleya National Research Center for Epidemiology and Microbiology has announced the complete disappearance of cancerous metastases in the first patient treated with a personalized Russian vaccine for melanoma. The center confirmed that no new tumors have appeared in the patient over the past four months, and that he will remain under medical observation for the next three years.
The vaccine, dubbed "NEOONCOVAC"—which received clinical approval in early December—utilizes messenger RNA (mRNA) technology. It is custom-designed for each individual patient based on their unique genetic profile, serving to "train" and stimulate the immune system to recognize and destroy cancer cells.
While this result is significant, researchers at the center have emphasized the need to balance optimism with scientific caution. They noted that the disappearance of metastases in this first patient is a positive and important indicator, but it is not sufficient to draw definitive conclusions until the success is replicated in dozens of other patients through expanded clinical trials.